Memorial Sloan Kettering confirms immunomodulatory effects on Maitake extract.
Materia medica, Vegetable (Usage)
Materia medica, Vegetable (Health aspects)
Materia medica, Vegetable (Research)
Plant extracts (Usage)
Plant extracts (Health aspects)
Plant extracts (Research)
|Publication:||Name: Townsend Letter Publisher: The Townsend Letter Group Audience: General; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2008 The Townsend Letter Group ISSN: 1940-5464|
|Issue:||Date: August-Sept, 2008 Source Issue: 301-302|
|Topic:||Event Code: 310 Science & research|
|Organization:||Organization: Memorial Sloan-Kettering Cancer Center (New York, New York); American Society of Clinical Oncology|
|Geographic:||Geographic Scope: United States|
At the Annual Meeting of American Society of Clinical Oncology
(ASCO) in Chicago (May 30-June 3, 2008), Memorial Sloan Kettering Cancer
Center (MSKCC) announced the results of a government-funded clinical
study, begun in 2004, which confirms the immunomodulatory effects of
Maitake extracts as well as "no dose-limiting toxicity." The
MSKCC study also concluded that the clinical significance is as yet
unknown. The study was conducted on a crude extract from maitake
mushroom (Crifola frondosa). In 2004, researchers at MSKCC, together
with Cornell University Medical College, published the result of another
laboratory study that showed a significant enhancement of bone marrow
colony formation with the use of crude Maitake extracts as well as a
reduction in the toxicity induced by an anticancer drug. (1)
Mike Shirota, CEO of Maitake Products, Inc., welcomes the study: "Our Grifron[R]--Pro Maitake D-Fraction[R] has already been under a clinical trial with advanced breast and prostate cancer patients under Investigational New Drug (IND) approval by the FDA. The new clinical study at MSKCC, one of the nation's most prominent cancer institutes, will significantly strengthen scientific validation of Maitake extracts, although it was not carried out on a purified and standardized extract like our Grifron[R] Pro Maitake D-Fraction[R]." Maitake Products, Inc. is an official Corporate Cancer Research Sponsor of the Memorial Sloan Kettering Cancer Center.
Maitake Products Inc.'s Maitake D-Fraction[R] line of Maitake extract products are the only ones available commercially that have been made for over a decade with an established active proteoglucan (D-fraction) standardization. (2) Maitake D-Fraction[R], PD Fraction[R], TD-Fraction[R], TMD Fraction[R], Grifron[R], Mushroom Wisdom[R], ProstMate[R], Mushroom Emperors[TM], and MD Fraction[TM] are registered trademarks or trademarks of Maitake Products, Inc.
(1.)Hong Lin, et al. Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro. Internationa! Immunopharmacology. 2004;4: 91-99 .(This study was not conducted on a finished product available in the market, such as Maitake Products Inc.'s MD Fraction[TM])
(2.)Ikuko Hishida, et al. Antitumor activity exhibited by orally administered extract from fruit body of Crifohi frondosa (maitake). Chem. Pharm. Bull. 1988;36(5):1819-1827. (This study was not conducted on a finished product available in the market, such as Maitake Products Inc.'s Maitake D-Fraction[R]).
|Gale Copyright:||Copyright 2008 Gale, Cengage Learning. All rights reserved.|